# A Study of Hansoh (HS)-10502 in Patients With Advanced Solid Tumors

Source: https://onco.cc/trials/nct05740956/  
OnCo record `nct05740956` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

This study tests a PARP inhibitor; the registry reports that it is recruiting.

## Summary

The registry lists NCT05740956 as recruiting, last updated 2025-06-05. Enrolment is 318 planned participants, an estimate. Interventions: HS-10502. Primary measures include Maximum tolerated dose (MTD) of HS-10502（Stage 1）; Maximum applicable dose (MAD) of HS-10502（Stage 1）. No results are posted in the registry; this does not exclude separate publications.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-10-06
- Registry id: NCT05740956
- Phase: 1
- Setting: A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HS-10502 in Patients With Advanced Solid Tumors
- Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd.

## Sources

- ClinicalTrials.gov NCT05740956: https://clinicaltrials.gov/study/NCT05740956

## Connected records

- cancers: [Breast cancer (all types)](https://onco.cc/cancers/breast-cancer/), [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Ovarian cancer](https://onco.cc/cancers/ovarian/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/), [Prostate cancer](https://onco.cc/cancers/prostate/)
- targets: [PARP](https://onco.cc/targets/parp/)
- drugs: [HS-10502](https://onco.cc/drugs/hs-10502/)

---
JSON: https://onco.cc/api/v1/entities/nct05740956.json